Expression of c-Jun in hepatocellular carcinoma and its significance

doi:10.3877/cma.j.issn.2095-3232.2015.04.014

Abstract

Abstract:

Objective

To investigate the expression of c-Jun in hepatocellular carcinoma (HCC) and its correlation with prognosis.

Methods

Clinical data of 137 patients with HCC undergoing hepatectomy in the Third Affiliated Hospital of Sun Yat-sen University between Janunary 2010 and December 2013 were retrospectively studied. Among the 137 patients, 112 were males and 25 were females with the age ranging from 26 to 73 years old and the median of 45 years old. The informed consents of all patients were obtained and the local ethical committee approval had been received. The expression of c-Jun in HCC tissues was detected by immunohistochemistry. The patients were divided into the high-expression group (n=75) and low-expression group (n=62) according to the scores of immunohistochemical staining. The clinicopathological parameters and the correlation between c-Jun expression and prognosis of the two groups were analyzed. Comparison on clinicopathological parameters was conducted using Chi-square test and survival analysis was conducted using Kaplan-Meier and Log-rank test.

Results

The expression of c-Jun in HCC was correlated with HBsAg, alpha-fetoprotein (AFP), tumor size, tumor capsule and tumor vascular invasion (χ²=5.27, 32.68, 4.86, 1.04, 4.62; P<0.05). The 3-, 5-year cumulative survival rate of the high-expression group was respectively 64.14% and 41.20% and those of the low-expression group was respectively 72.04% and 61.21%. The overall survival of the high-expression group was significantly lower than that of the low-expression group (χ²=5.19, P<0.05).

Conclusion

c-Jun may play an important role in the occurrence and development of HCC and high expression of c-Jun indicates poor prognosis.

Key words: Carcinoma, hepatocellular, c-Jun, Prognosis

Yuewu Yang, Zhiqiang Ye, Qinglei Kong, Gangjian Luo. Expression of c-Jun in hepatocellular carcinoma and its significance[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(04): 250-253.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2015.04.014

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2015/V04/I04/250

Figures/Tables 1

References 19

[1]	Kang TW, Lim HK, Lee MW, et al. Perivascular versus nonperivascular small HCC treated with percutaneous RF ablation: retrospective comparison of long-term therapeutic outcomes[J]. Radiology, 2014, 270(3): 888-899.
[2]	范上达，邱宗祥，潘冬平．肝癌的综合治疗[J]．中华消化外科杂志, 2011, 10(4): 241-246.
[3]	Daniele A, Divella R, Quaranta M, et al. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization[J]. Clin Biochem, 2014, 47(3): 184-190.
[4]	Finkelmeier F, Bettinger D, Köberle V, et al. Single measurement of hemoglobin predicts outcome of HCC patients[J]. Med Oncol, 2014, 31(1): 806.
[5]	郭宇，陈规划．肝细胞肝癌合并肝静脉、下腔静脉及右心房癌栓的诊断与治疗[J/CD]．中华肝脏外科手术学电子杂志，2013,2(1): 53-55.
[6]	安玉玲，张婷婷，蔡常洁．西罗莫司用于治疗肝癌肝移植术后肿瘤复发患者的疗效分析[J]．器官移植，2011, 2(2): 73-76.
[7]	Kim S, Lee J, Lee SK, et al. Protein kinase C-αdownregulates estrogen receptor-αby suppressing c-Jun phosphorylation in estrogen receptor-positive breast cancer cells[J]. Oncol Rep, 2014, 31(3): 1423-1428.
[8]	Yang Z, Zhang Y, Wang L. A feedback inhibition between miRNA-127 and TGFbeta/c-Jun cascade in HCC cell migration via MMP13[J]. PLoS One, 2013, 8(6):e65256.
[9]	Rana A, Rana B, Mishra R, et al. Mixed lineage Kinase-c-Jun N-Terminal kinase axis: a potential therapeutic target in cancer[J]. Genes Cancer, 2013, 4(9/10): 334-341.
[10]	Tinzl M, Chen B, Chen SY, et al. Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer[J]. PLoS One, 2013, 8(11): e79573.
[11]	Shao J, Teng Y, Padia R, et al. COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis[J]. Neoplasia, 2013, 15(9): 1075-1085.
[12]	Eckhoff K, Flurschütz R, Trillsch F, et al. The prognostic significance of Jun transcription factors in ovarian cancer[J]. J Cancer Res Clin Oncol, 2013, 139(10): 1673-1680.
[13]	Li Z, Zhu Y, Yu M, et al. c-Jun is involved in interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human bladder cancer T24 cells[J]. Urol Oncol, 2013, 31(2): 228-233.
[14]	Yuan F, Xu Z, Yang M, et al. Overexpressed DNA polymerase iota regulated by JNK/c-Jun contributes to hypermutagenesis in bladder cancer[J]. PLoS One, 2013, 8(7): e69317.
[15]	Guo H, Xu YM, Ye ZQ, et al. Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IκBα, c-Jun and androgen receptor[J]. Pharmazie, 2013, 68(6): 431-434.
[16]	Gonzalez-Villasana V, Gutiérrez-Puente Y, Tari AM. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells[J]. Oncol Rep, 2013, 30(3): 1506-1510.
[17]	Zhang H, Yu C, Dai J, et al. Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of beta-catenin activation of the DKK1 promoter in prostate cancer[J]. Oncogene, 2014, 33(19): 2464-2477.
[18]	Cao Z, Zhang R, Li J, et al. X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis[J]. J Biol Chem, 2013, 288(28): 20238-20247.
[19]	Hu L, Xia L, Zhou H, et al. TF/FVⅡa/PAR2 promotes cell proliferation and migration via PKCα and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620[J]. Tumour Biol, 2013, 34(5): 2573-2581.

组别	例数	年龄（岁）		HBsAg		AFP（μg/L）		肝硬化		肿瘤直径（cm）		肿瘤数目		肿瘤包膜		肿瘤血管侵犯		TNM分期
组别	例数	≤45	>45	阴性	阳性	≤20	>20	无	有	≤3	>3	单个	多个	无	有	无	有	I～Ⅱ	Ⅲ～Ⅳ
高表达组	75	35	40	60	15	17	58	37	38	22	53	48	27	26	49	49	26	61	14
低表达组	62	28	34	37	25	21	41	31	31	33	29	38	24	36	26	51	11	51	11
χ²值	?	35.89		5.27		32.68		39.21		4.86		31.69		1.04		4.62		14.84
P值	?	>0.05		<0.05		<0.05		>0.05		<0.05		>0.05		<0.05		<0.05		>0.05

组别	例数	年龄（岁）		HBsAg		AFP（μg/L）		肝硬化		肿瘤直径（cm）		肿瘤数目		肿瘤包膜		肿瘤血管侵犯		TNM分期
组别	例数	≤45	>45	阴性	阳性	≤20	>20	无	有	≤3	>3	单个	多个	无	有	无	有	I～Ⅱ	Ⅲ～Ⅳ
高表达组	75	35	40	60	15	17	58	37	38	22	53	48	27	26	49	49	26	61	14
低表达组	62	28	34	37	25	21	41	31	31	33	29	38	24	36	26	51	11	51	11
χ²值	?	35.89		5.27		32.68		39.21		4.86		31.69		1.04		4.62		14.84
P值	?	>0.05		<0.05		<0.05		>0.05		<0.05		>0.05		<0.05		<0.05		>0.05

Please choose a citation manager

Content to export